drugset / Trial / NCT00804310
Lapatinib and Ixabepilone in Treating Patients With Advanced Solid Tumors
Phase 1
Terminated
5 enrolled
University of California, Davis
Bristol-Myers Squibb · collabGenentech, Inc. · collabNational Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment
Summary
RATIONALE: Lapatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as ixabepilone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving lapatinib together with ixabepilone may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of lapatinib given together with ixabepilone in treating patients with advanced solid tumors.
Timeline
- Start
- 2009-08
- Primary completion
- 2011-08
- Completion
- 2011-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ixabepilone | Small molecule | 15 mg/m2 | Intravenous |
| Subject | Ixabepilone | Small molecule | 20 mg/m2 | Intravenous |
| Subject | Lapatinib | Small molecule | 1000 mg | Oral |
| Subject | Lapatinib | Small molecule | 1500 mg | Oral |